METHODOLOGY FOR CALCULATION OF AVOIDABLE MORTALITY ON THE EXAMPLE OF CARDIOVASCULAR DISEASES IN KAZAKHSTAN
Introduction. Cardiovascular disease (CVD) related mortality remains a major preventable public health problem worldwide. A high rate of avoidable mortality indicates insufficient preventive or effective medical care that was not provided in a timely manner. However, avoidable mortality can be an indicator of health system performance. OECD countries and Canada use the measure of avoidable mortality to study the trend in causes of death.
The aim of the study is to analyze preventable CVD mortality in the Republic of Kazakhstan.
Materials and methods: To calculate avoidable, treatable and preventive mortality rates, we summed the standardized mortality rate (tst) by age group, including cause of death. Based on the methodology developed by the OECD, we determined the avoidable mortality for CVD in Kazakhstan in 2018. Data for Kazakhstan were taken by "Information and Computing Center of the Bureau of National Statistics of the Agency for Strategic Planning and Reforms of the Republic of Kazakhstan"
Results: In the Republic of Kazakhstan from CVD, the age-standardized rates of avoidable mortality per 100,000 population amounted to 121.42 (of which 58.36 are preventive and 63.06 are treatable). It was found that the older the age of the population, the higher the rates of both preventive and treatable mortality.
Conclusion: Despite the introduction of preventive programs for CVD and disease management programs, the proportion of mortality associated with curable conditions exceeds, which indicates an insufficient amount of implementation of measures for the prevention of CVD.
Lyazzat Kosherbayeva1, http://orcid.org/0000-0001-8376-4345
Aizhan Samambaeva2, http://orcid.org/0000-0001-8600-7980
Yolanda Pena Boquete2, http://orcid.org/0000-0002-8884-2223
Aziza Imamatdinova1
1 Asfendiyarov Kazakh National Medical University, Almaty, Republic of Kazakhstan;
2 AYeconomics Research Centre S.L., Santiago de Compostela, Spain.
1. Avoidable mortality: OECD/Eurostat lists of preventable and treatable causes of death (January 2022 version) https://www.oecd.org/health/health-systems/Avoidable-mortality-2019-Joint-OECD-Eurostat-List-preventable-treatable-causes-of-death.pdf (Access 04.22).
2. Bahk J., Jung-Choi K. The Contribution of Avoidable Mortality to the Life Expectancy Gains in Korea between 1998 and 2017 // Int J Environ Res Public Health. 2020 Sep 7;17(18):6499. doi: 10.3390/ijerph17186499.
3. Boisclair D., Décarie Y., Laliberté-Auger F., Michaud P.C., Vincent C. The economic benefits of reducing cardiovascular disease mortality in Quebec, Canada // PLoS One. 2018 Jan 4. 13(1):e0190538. doi: 10.1371/journal.pone.0190538.
4. Canadian Institute for Health Information. Health indicators 2012. Ottawa, Ontario: Canadian Institute for Health Information; 2012. Available at https://secure.cihi.ca/free_products/health_indicators_2012_en.pdf. (Access 04.22).
5. Centers for Disease Control and Prevention (CDC). Vital signs: avoidable deaths from heart disease, stroke, and hypertensive disease - United States, 2001-2010. MMWR Morb Mortal Wkly Rep. 2013 Sep 6;62(35):721-7. (Access 04.22).
6. Ford E.S., Capewell S. Proportion of the decline in cardiovascular mortality disease due to prevention versus treatment: public health versus clinical care // Annu Rev Public Health. 2011. 32:5-22. doi: 10.1146/annurev-publhealth-031210-101211.
7. Ford E.S. Trends in predicted 10-year risk of coronary heart disease and cardiovascular disease among U.S. adults from 1999 to 2010 // J Am Coll Cardiol. 2013 Jun 4;61(22):2249-52. doi: 10.1016/j.jacc.2013.03.023.
8. Gheorghe A., Griffiths U., Murphy A., Legido-Quigley H., Lamptey P., Perel P. The economic burden of cardiovascular disease and hypertension in low- and middle-income countries: a systematic review // BMC Public Health. 2018 Aug 6;18(1):975. doi: 10.1186/s12889-018-5806-x.
9. Greer S., Schieb L.J., Ritchey M., George M,. Casper M. County Health Factors Associated with Avoidable Deaths from Cardiovascular Disease in the United States, 2006-2010 // Public Health Rep. 2016 May-Jun;131(3):438-48. doi: 10.1177/003335491613100310.
10. Heijink R., Koolman X., Westert G.P. Spending more money, saving more lives? The relationship between avoidable mortality and healthcare spending in 14 countries // Eur J Health Econ. 2013 Jun. 14(3):527-38. doi: 10.1007/s10198-012-0398-3.
11. James P.D., Wilkins R., Detsky A.S., Tugwell P., Manuel D.G. Avoidable mortality by neighbourhood income in Canada: 25 years after the establishment of universal health insurance // J Epidemiol Community Health. 2007 Apr;61(4):287-96. doi: 10.1136/jech.2006.047092.
12. Joumard, R., & Gudmundsson, H. (Eds.) (2010). Indicators of environmental sustainability in transport: An interdisciplinary approach to methods. European Commission. RECHERCHES No. R282 http://cost356.inrets.fr/
13. Kossarova L., Holland W., Mossialos E. 'Avoidable' mortality: a measure of health system performance in the Czech Republic and Slovakia between 1971 and 2008 // Health Policy Plan. 2013 Aug. 28(5):508-25. doi: 10.1093/heapol/czs093.
14. Macinko J., Elo I.T. Black-white differences in avoidable mortality in the USA, 1980-2005 // J Epidemiol Community Health. 2009 Sep;63(9):715-21. doi: 10.1136/jech.2008.081141.
15. Nolte E., McKee C.M. In amenable mortality--deaths avoidable through health care--progress in the US lags that of three European countries // Health Aff (Millwood). 2012 Sep.31(9):2114-22. doi: 10.1377/hlthaff.2011.0851.
16. OECD/Eurostat. Avoidable mortality: OECD/Eurostat lists of preventable and treatable causes of death (November 2019 version). – 2019. (Access 04.22).
17. Office for National Statistics. Avoidable mortality in england and wales 2015. – 2017.
18. Plug I., Hoffmann R., Mackenbach J.P. AMIEHS. Avoidable mortality in the European Union: towards better indicators for the effectiveness of health systems. Final report. Department of Public Health, Erasmus Medical Center Rotterdam. – 2011. (Access 04.22).
19. Roth G.A., Mensah G.A., Johnson C.O., Addolorato G., Ammirati E., and etc.; GBD-NHLBI-JACC Global Burden of Cardiovascular Diseases Writing Group. Global Burden of Cardiovascular Diseases and Risk Factors, 1990-2019: Update From the GBD 2019 Study // J Am Coll Cardiol. 2020 Dec 22. 76(25):2982-3021. doi: 10.1016/j.jacc.2020.11.010.
20. Rutstein D.D., Berenberg W., Chalmers T.C., Child C.G., Fishman A.P., Perrin E.B. Measuring the quality of medical care. A clinical method // N Engl J Med. 1976 Mar 11. 294(11):582-8. doi: 10.1056/NEJM197603112941104.
21. Shaw L.J., Goyal A., Mehta C., Xie J., Phillips L., Kelkar A., Knapper J., Berman D.S., Nasir K., Veledar E., Blaha M.J., Blumenthal R., Min J.K., Fazel R., Wilson P.W.F., Budoff M.J. 10-Year Resource Utilization and Costs for Cardiovascular Care // J Am Coll Cardiol. 2018 Mar 13. 71(10):1078-1089. doi: 10.1016/j.jacc.2017.12.064.
22. Towfighi A., Saver J.L. Stroke declines from third to fourth leading cause of death in the United States: historical perspective and challenges ahead // Stroke. 2011 Aug. 42(8):2351-5. doi: 10.1161/STROKEAHA.111.621904.
23. UK Office for National Statistics Consultation on Definitions of Avoidable Mortality. London: Her Majesty’s Stationery Office (HMSO) 2011 Available online: http://www.ons.gov.uk/ons/about-ons/get-involved.pdf [(accessed on 20 May 2020)]
24. Walker I.F., Garbe F., Wright J., Newell I., Athiraman N., Khan N., Elsey H. The Economic Costs of Cardiovascular Disease, Diabetes Mellitus, and Associated Complications in South Asia: A Systematic Review // Value Health Reg Issues. 2018 May. 15:12-26. doi: 10.1016/j.vhri.2017.05.003.
25. Zygmunt A., Kendall C.E., James P., Lima I., Tuna M., Tanuseputro P. Avoidable Mortality Rates Decrease but Inequity Gaps Widen for Marginalized Neighborhoods: A Population-Based Analysis in Ontario, Canada from 1993 to 2014 // J Community Health. 2020 Jun. 45(3):579-597. doi: 10.1007/s10900-019-00778-8.
Number of Views: 90
Category of articles:
Original articles
Bibliography link
Kosherbayeva L., Samambaeva A., Boquete Yolanda Pena, Imamatdinova A. Methodology for calculation of avoidable mortality on the example of cardiovascular diseases in Kazakhstan // Nauka i Zdravookhranenie [Science & Healthcare]. 2022, (Vol.24) 4, pp. 101-107. doi 10.34689/SH.2022.24.4.013Related publications:
ANALYSIS OF CLINICAL AND DEMOGRAPHIC INDICATORS OF PATIENTS WITH PARKINSON'S DISEASE IN THE SOUTHERN REGION OF KAZAKHSTAN
A COMPARATIVE STUDY OF DRUG POLICY REGARDING ORPHAN DISEASES IN THE USA, THE EUROPEAN UNION, AND THE REPUBLIC OF KAZAKHSTAN
MUTATIONS IN CARDIAC ION CHANNEL GENES IN KAZAKHSTANI PATIENTS WITH LONG QT SYNDROME
GENETIC FEATURES OF CONGENITAL DYSFUNCTION OF THE ADRENAL CORTEX CAUSED BY 21-HYDROXYLASE DEFICIENCY IN PERSONS OF KAZAKH NATIONALITY
NON-MOTOR SYMPTOMS IN PARKINSON'S DISEASE USING THE EXAMPLE OF AKTOBE PATIENTS